The chief executive of the Danish insulin-maker suggested that Novo Nordisk will be sitting out the frenzy of deal-making that has convulsed the global pharmaceutical industry.
via WSJ.com: US Business http://ift.tt/1vNCjts
via WSJ.com: US Business http://ift.tt/1vNCjts
Nessun commento:
Posta un commento